Valuation — not yet established
No valuation for Inflammatix is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($213.5M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Inflammatix
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Sep 2024 | Later Stage VC (Series E) | $57.0M | ▮ | ▮ |
| Sep 2021 | Later Stage VC (Series D) | $102.4M | ▮ | ▮ |
| Jan 2020 | Early Stage VC | $32.1M | ▮ | ▮ |
How Inflammatix's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Inflammatix, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Inflammatix raised?
- Inflammatix has raised $213.5M in total funding across 3 recorded rounds.
- When did Inflammatix last raise?
- Inflammatix last raised in Sep 2024 (Later Stage VC (Series E)), raising $57.0M.